Privia Health's Third Quarter Will Test Whether Deceleration Is a Speed Bump or a Signal

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Privia Health reports before the market open, meaning Day 0 captures the first full trading session where investors react to results, while Day +1 reflects follow-through sentiment.

Privia Health has exhibited significant volatility around earnings, with an average absolute Day 0 move of 5.43% and an average Day 0 range of 10.03%. The most recent report (August 2026) saw the stock drop 8.18% despite beating revenue estimates, illustrating how profitability misses can overshadow top-line strength.

The largest single-day reaction came in February 2026, when shares surged 9.98% on Day 0, followed by a 4.66% pullback the next session. Conversely, the May 2026 report triggered a flat Day 0 response but a 3.88% decline on Day +1, suggesting delayed negative sentiment.

Day +1 moves average 3.24% in absolute terms with a 5.44% range, indicating that follow-through action is meaningful but typically less dramatic than the initial reaction. Investors should prepare for potential swings in the 5-10% range on the day of the report, with the direction heavily dependent on whether Privia can demonstrate progress on profitability and margin expansion.

Part 2.2: Options Market Expected Move

The options market is pricing a 4.40% expected move by the November 20 expiration, which is notably below the stock's historical average Day 0 move of 5.43%. This suggests options traders may be underestimating potential volatility, particularly given Privia's recent pattern of large earnings surprises and the heightened focus on profitability metrics this quarter.

Part 3: What Analysts Are Saying

Current Consensus and Ratings Breakdown

Analysts maintain a strongly bullish stance on Privia Health, with an average recommendation of 4.68 out of 5.00. The consensus includes 15 Strong Buy ratings, 2 Moderate Buy ratings, and 2 Hold ratings, with no sell recommendations. This reflects broad confidence in the company's physician enablement model and value-based care strategy.

The average price target of $31.47 implies 40.5% upside from the current $22.40 level. The range spans from a low of $24.00 to a high of $40.00, indicating some divergence in views on valuation and execution risk.

Sentiment Trend

Analyst sentiment has remained unchanged over the past month, with the same 4.68 rating and identical distribution of recommendations. This stability suggests the Street is taking a wait-and-see approach heading into the Q3 report, with most firms holding their views steady rather than making significant revisions.

Upside Potential

The consensus target of $31.47 represents substantial upside from current levels, reflecting Wall Street's view that Privia's platform economics and value-based care positioning justify a premium valuation. However, the wide target range—from $24.00 to $40.00—highlights the uncertainty around near-term profitability and the company's ability to navigate sector headwinds. Bulls see Privia as a differentiated play on physician enablement with meaningful room for adoption, while more cautious analysts point to execution challenges and the competitive landscape as reasons for a more measured outlook.

Part 4: Technical Picture

Barchart Technical Opinion

The Barchart Technical Opinion currently registers a Sell signal at 24%, unchanged from last week's 24% reading but significantly improved from last month's 88% Sell signal. This dramatic shift over the past month suggests the stock has stabilized after a period of technical weakness, though the signal remains cautious heading into earnings.

Timeframe Analysis

• Short-term (Hold): Neutral reading indicates the stock is consolidating in the near term, with no clear directional bias as investors await the earnings catalyst
• Medium-term (50% Sell): Moderate sell signal reflects some weakness in the intermediate timeframe, suggesting the stock has struggled to build sustained upward momentum
• Long-term (50% Sell): Moderate sell signal indicates the longer-term trend remains under pressure, with the stock trading below key moving averages

Trend Characteristics: The signal strength is classified as Weak with a Weakening direction, suggesting the technical setup lacks conviction and momentum is fading as the stock approaches the earnings release.

Privia Health is trading at $22.40, positioned above its 5-day ($21.73), 10-day ($21.98), 20-day ($21.93), and 50-day ($20.91) moving averages, indicating short-term strength. However, the stock remains below its 100-day ($22.66) and 200-day ($22.64) moving averages, signaling longer-term resistance overhead.

The technical picture is mixed: while the stock has bounced from recent lows and reclaimed short-term support, it faces a critical test at the $22.64-$22.66 zone where the 100-day and 200-day averages converge. A strong earnings report could provide the catalyst to break through this resistance and shift the longer-term trend, while a disappointment could send shares back toward the $21 support level. The weak and weakening trend characteristics suggest limited technical momentum heading into the release, making the fundamental results all the more important for determining the next directional move.